formulation excipient

mRNA-Encapsulating Lipid Excipient 1 (Compound 2), a thiocarbamate-based ionizable lipid, serves as an excipient in the formulation of mRNA-encapsulating lipid nanoparticles [1].

DSPE-Fluorescein is a phospholipid known for its excellent biocompatibility and pronounced amphiphilic properties, making it an ideal and prominent excipient or formulation agent in pharmaceuticals to achieve enhanced therapeutic outcomes. [DSPE-Fluorescein] is also applicable in research on drug delivery.

DOPE-PEG-FITC (MW 2000) is a phospholipid known for its excellent biocompatibility and significant amphiphilic properties, making it a primary and suitable excipient or formulation in drug delivery systems for enhanced therapeutic outcomes. Additionally, DOPE-PEG-FITC (MW 2000) is useful in research focused on drug delivery mechanisms.

DOPE-PEG-Azide (MW 3400) is a phospholipid known for its excellent biocompatibility and pronounced amphiphilic properties, making it a key and suitable excipient or formulation in drug delivery systems for enhanced therapeutic outcomes. It is utilized in research focused on drug delivery.

DOPE-PEG-Azide (MW 5000) is a phospholipid known for its excellent biocompatibility and notable amphiphilic properties, making it an ideal component as a formulation type or excipient in pharmaceuticals for enhanced therapeutic outcomes. It is utilized in drug delivery research.

DOPE-PEG-FITC (MW 5000) is a phospholipid known for its excellent biocompatibility and distinct amphiphilic properties, making it an ideal and primary excipient or formulation in pharmaceuticals to enhance therapeutic outcomes. Additionally, DOPE-PEG-FITC (MW 5000) is utilized in research focused on drug delivery.

DOPE-PEG-Cy5.5 (MW 2000) is a phospholipid known for its excellent biocompatibility and pronounced amphiphilic properties, making it a key and suitable excipient or formulation in pharmaceuticals to enhance therapeutic outcomes. DOPE-PEG-Cy5.5 (MW 2000) is applicable in drug delivery research.

DOPE-PEG-Cy5 (MW 5000) is a phospholipid. With excellent biocompatibility and notable amphiphilic properties, phospholipids serve as a primary and suitable formulation or excipient in drug delivery systems, enhancing therapeutic outcomes. DOPE-PEG-Cy5 (MW 5000) is applicable in studies focused on drug delivery.

DOPE-PEG-Cy5.5 (MW 5000) is a phospholipid known for its excellent biocompatibility and significant amphiphilic properties, making it an ideal and primary formulation or excipient in drug delivery to enhance therapeutic efficacy. This compound is applied in research focused on drug delivery methods.

DOPE-PEG-Cy5 (MW 2000) is a phospholipid known for its excellent biocompatibility and significant amphiphilic properties, making it an ideal and essential excipient or formulation type in pharmaceuticals for enhanced therapeutic outcomes. It is applicable in research focusing on drug delivery.

DMPE-PEG-amine (TFA) (MW 2000) is a phospholipid noted for its excellent biocompatibility and significant amphiphilic properties, making it a suitable and key excipient or formulation in drug delivery systems to achieve enhanced therapeutic outcomes. Additionally, DMPE-PEG-amine (TFA) (MW 2000) is applicable in drug delivery research.

Maltodextrin, with a dextrose equivalent (DE) of 5.0-8.0, can be utilized as an excipient in pharmaceuticals. Excipients, also known as auxiliary agents, are chemical substances employed in drug formulation to support the active ingredients. Typically, they are non-active components that enhance the stability, solubility, and manufacturability of the drug formulation. Additionally, excipients can impact the absorption, distribution, metabolism, and elimination (ADME) processes of combined medications. The DE value indicates the number of reducing-end aldehyde groups relative to pure glucose at the same concentration; hence, a higher DE signifies a higher rate of hydrolysis conversion and a lower average molecular weight.